← Back to Clinical Trials
Recruiting NCT07208851

NCT07208851 Developing a Booster Session for Problem Management Plus in the Bahamas: A Pilot Randomized Controlled Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07208851
Status Recruiting
Phase
Sponsor The New School
Condition Depression Symptoms
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2024-10-16
Primary Completion 2026-07-31

Trial Parameters

Condition Depression Symptoms
Sponsor The New School
Study Type INTERVENTIONAL
Phase N/A
Enrollment 50
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-10-16
Completion 2026-07-31
Interventions
Problem Management Plus booster session

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Therapists at the Grand Bahama Resilience Center (GBRC) will be trained to deliver Problem Management Plus (PM+), a WHO intervention. Then, those therapists will deliver PM+ (5 one-on-one skills-based sessions) to a total of 50 adult clients experiencing mild to moderate mental health difficulties (excluding anyone with cognitive difficulties or psychosis). Participants will complete (de-identified) self-report survey assessments before PM+, after PM+, 3 months later, and 6 months later. After receiving 5 sessions of PM+, participants will be randomized to either receive a one-time booster session of PM+ (to be co-created by the PI and the GBRC providers) three months later or to a control group which will receive a phone call reminding them that they will receive their third assessment soon.

Eligibility Criteria

Inclusion Criteria: * Adults of 18 years or above * English-speaking * A score of \<91 on Global Assessment of Functioning * Located in the Bahamas Exclusion Criteria: * ● Imminent suicide risk (assessed at screening using Columbia Suicide-Severity Rating Scale, see document titled " Screener updated 10-30- 24") * Severe mental disorder (e.g. psychotic disorders) * Severe cognitive impairment (e.g. severe intellectual disability or dementia)

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology